



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



“Portal vein thrombosis occurring after the first dose of mRNA SARS-CoV-2 vaccine in a patient with antiphospholipid syndrome”

ARTICLE INFO

Keywords

Portal vein thrombosis
Antiphospholipid syndrome
mRNA SARS-CoV-2 vaccine

Dear Editor,

With the implementation of a global vaccination plan, the year 2021 began with the hope of definitively conquering the coronavirus disease 2019 (COVID-19) pandemic. The European Medicines Agency (EMA) has approved four vaccines, two of which are based on mRNA technology (BNT162b2 and mRNA-1273) and two of which employ an adenovirus vector (ChAdOx1-S and Ad26.COV2) [1]. The EMA Pharmacovigilance Risk Assessment Committee (PRAC) has recently assessed the safety profile of ChAdOx1-S following many reports of blood clotting events emerging days to weeks after the vaccine's first or second injection [2]. Following the report of six cases of thrombocytopenia and cerebral venous sinus thrombosis in female recipients aged 18–48 years, the Food and Drug Administration (FDA) suspended the use of the AD26.COV2 vaccine in the United States (US) in April 2021 [3]. This type of vaccine-induced immune thrombotic thrombocytopenia (VITT), also called thrombotic thrombocytopenia (TTS), implies an immunological reaction that mimics heparin-induced thrombocytopenia (HIT) [4]. SARS-CoV-2 infection is linked to an increase in venous thromboembolic (VTE) events, most likely because of a thrombotic state caused by inflammation and immune-mediated thrombosis [5]. More recently, some rare cases of classical VTE have been observed in citizens who received the mRNA-based vaccine (BNT162b2/Comirnaty/Pfizer/BioNTech) [6–8]. However, the link between COVID-19 vaccinations and thrombotic events remains unknown, while an immune-mediated mechanism analogous to what occurs in antiphospholipid syndrome (APS) could be a possibility. Furthermore, the majority of those who developed severe coagulation disorders after being vaccinated were young women, who are also the APS target population [9,10].

A 68-year-old woman presented to the emergency department (ED) complaining of abdominal pain, in the epigastrium and in the right hypochondrium. She had a mild fever and a slight increase of CRP, without any obvious site of infection and no history of trauma. She received the first dose of mRNA SARS-CoV-2 vaccine (BNT162b2/Comirnaty/Pfizer/BioNTech) subcutaneously, without any reported clinical problem 14 days before presentation. Her past medical history included obesity (first degree, with body mass index 30,1 kg/m²), asthma, hypothyreosis, and irritable bowel syndrome (IBS-D). She had a

miscarriage many years ago, early in pregnancy (before week 10). She had no history of thrombosis or abortions in the past, as well as pre-existing autoimmune diseases. She had 3 normal pregnancies without complications afterward. She did not smoke. The physical examination was unremarkable. The complete blood count, the comprehensive metabolic panel, and the coagulation profile was unremarkable. D-dimer test was not performed. A Color-Doppler ultrasound revealed thrombosis of the portal vein. Evaluation with chest-abdomen-pelvis Computer Tomography Scan (CT) was negative for malignancy and liver cirrhosis. Thrombophilia screening was negative. Notably, IgG Beta-2 glycoprotein I antibodies were elevated (28 U/ml), and lupus anticoagulant was positive. Anti-cardiolipin antibodies was negative. Repeated positivity of lupus anticoagulant and IgG Beta-2 glycoprotein I antibodies, 12 weeks after first abnormal blood tests, confirmed the diagnosis of Antiphospholipid Syndrome (APS). The patient is being treated with Warfarin. Repeated Color-Doppler ultrasound revealed resolution of thrombosis, 3 months later.

To my knowledge, this is the first reported case of manifestation of APS in the form of portal vein thrombosis after the first dose of mRNA vaccine (BNT162b2/Comirnaty/Pfizer/BioNTech). It is supposed that pre-existent antiphospholipid antibodies (aPLs) might predispose to this complication, acting as the first trigger, although this is not determined a priori. Given the clinical resemblance between thrombotic events following COVID-19 vaccination and APS, researchers from Italy provided a pathogenic theory for this rare adverse event that involves a pre-existent or a de novo aPL positivity. While adenoviral vector-based vaccines may induce the synthesis of aPLs due to a molecular mimicry mechanism, the mRNA-based vaccines may instead trigger a more complex pathway, characterized by activation of Toll-like receptor (TLR), generation of a Type I Interferon (IFN) response, NETosis and the direct initiation of the coagulation cascade. Disruption of the physiological cross-talk occurring between platelets and endothelial cells drives these cells toward a pro-inflammatory and pro-coagulant phenotype [11].

The fast development of currently available COVID-19 vaccines may create certain considerations about potential long-term safety issues, but still, the intervention's advantages in stopping the spread of the COVID-19 pandemic appear to outweigh the risks associated with a longer-term

<https://doi.org/10.1016/j.tru.2021.100069>

Received 26 July 2021; Received in revised form 30 August 2021; Accepted 2 September 2021

Available online 3 September 2021

2666-5727/© 2021 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

characterization of the pharmacological profile of these vaccines. To determinate the degree of this potential side effect which, while extremely low, it is required a longer follow-up and a larger diffusion of SARS-CoV-2 vaccines in the population. In addition, side effects occurring in a minority of people belonging to specific populations (like aPL-positive subjects) may be underestimated.

Funding information

No source of funding was declared for this study.

Informed consent

The author obtained informed consent from the patient involved in this report.

Declaration of competing interest

None declared.

Acknowledgement

None.

References

- [1] European Medicines Agency, Treatments and vaccines for COVID-19: authorized medicines. <https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/treatments-vaccines-covid-19-authorized-medicines# covid-19-vaccines-section>, 2021. (Accessed 15 February 2021).
- [2] European medicines agency, EMA/PRAC/157045/2021 pharmacovigilance risk assessment committee (PRAC). Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 vaccine (ChAdOx1-S [recombinant]) – covid-19 vaccine AstraZeneca (other viral vaccines). https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-chadox1-s-recombinant-covid_en.pdf, 2021.
- [3] Janssen FDA, COVID-19 Vaccine Frequently Asked Questions, 2021. <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/janssen-covid-19-vaccine-frequently-asked-questions>. (Accessed 15 April 2021).
- [4] N.H. Schultz, I.H. Sørvoll, A.E. Michelsen, et al., Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination, *N. Engl. J. Med.* (2021 Apr 9), <https://doi.org/10.1056/NEJMoa2104882>.
- [5] T. Iba, J.H. Levy, M. Levi, J. Thachil, Coagulopathy in COVID-19, *J ThrombHaemost* 18 (9) (2020) 2103–2109, <https://doi.org/10.1111/jth.14975>.
- [6] G. Carli, I. Nichele, M. Ruggeri, et al., Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine, *Intern Emerg Med* 16 (3) (2021) 803–804, <https://doi.org/10.1007/s11739-021-02685-0>.
- [7] L. Dias, R. Soares-Dos-Reis, J. Meira, et al., Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine, *J. Stroke Cerebrovasc. Dis.* 30 (8) (2021 May 25) 105906.
- [8] J.S. Al-Maqbali, et al., A 59-year-old woman with extensive deep vein thrombosis and pulmonary thromboembolism 7 Days following a first dose of the pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine, *Am J Case Rep* 22 (2021 Jun 12), e932946.
- [9] European Medicines Agency, COVID-19 Vaccine AstraZeneca, Benefits Still Outweigh the Risks Despite Possible Link to Rare Blood Clots with Low Blood Platelets, 2021. <https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots>.
- [10] E. Papadakis, A. Banti, A. Kioumi, Women's issues in antiphospholipid syndrome, *Isr. Med. Assoc. J.* 18 (2016) 524–529.
- [11] R. Talotta, E.S. Robertson, Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia: the straw that breaks the camel's back? *Cytokine Growth Factor Rev.* 60 (2021 Aug) 52–60. Epub 2021 May 28.

Nikolaos Melas

*Gastroenterology and Hepatology Department, Karlstad Central Hospital,
Rosenborgsgatan 9, 652 30, Karlstad, Sweden
E-mail address: nikolaos.e.melas@gmail.com.*